Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Coya Therapeutics, Inc.NASDAQ: COYA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$7.21M, compared with -$7.31M a year earlier. Trailing-twelve-month net income was -$21.13M.
Context
- Net income amounted to 267.1% of revenue in FY2025, down 151.6 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$25.16M (-18.5%) for the fiscal year ending Dec 2026, a step up from the -42.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.21M-26.2% QoQ
- Last fiscal yearDec 2025
- -$21.23M-42.6% YoY
- LTMMar 2026
- -$21.13M-23.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.4% | -33.1% | -34.4 pp |
| 1 year | -42.6% | -18.5% | +24.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (21.23M) USD
- Year-over-year change
- -42.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (21.23M) | -42.6% |
| FY2024 | 2024-12-31 | (14.88M) | -86.3% |
| FY2023 | 2023-12-31 | (7.99M) | +34.8% |
| FY2022 | 2022-12-31 | (12.24M) | -150.3% |
| FY2021 | 2021-12-31 | (4.89M) | — |
Net Income vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 net income of -$21.13M is the 2nd highest of the 11 companies compared; the peer median is -$45.05M.
- Its year-over-year change of -23.3% is the 7th highest of 11, against a peer median of -6.0%.
- Net income amounts to 266.1% of revenue for COYA, versus a peer median of 2663.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $110M | +489.6% | — | — | |
| LTM Mar 2026 | -$21.13M | -23.3% | — | 266.1% | |
| LTM Mar 2026 | -$24.17M | +3.2% | — | 339.3% | |
| LTM Mar 2026 | -$33.51M | -15.3% | — | 25009.7% | |
| LTM Mar 2026 | -$34.98M | -67.4% | — | — | |
| LTM Mar 2026 | -$40.23M | -45.6% | — | — | |
| LTM Mar 2026 | -$49.87M | +29.4% | — | 4987.4% | |
| LTM Mar 2026 | -$70.36M | -26.1% | — | 44.8% | |
| LTM Mar 2026 | -$113.22M | +48.4% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.81M | -519.4% | — | — |
| LTM Mar 2026 | -$124.13M | +44.6% | — | — | |
| Peer median (excluding COYA) | -$45.05M | -6.0% | — | 2663.4% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6M | 3.55M | 7.95M |
| Cost of Revenue | 0 | 4.41M | 5.5M | 11.87M | 27.36K |
| Gross Profit | 0 | (4.41M) | 500.68K | (8.31M) | 7.92M |
| Gross Margin | — | — | 8.3% | -233.9% | 99.7% |
| Research & Development | 2.54M | 4.94M | 6.04M | 11.89M | 16.73M |
| Selling, General & Admin | 2.31M | 4.85M | 7.83M | 8.89M | 11.45M |
| Operating Expenses | 4.87M | 5.4M | 8.4M | 8.94M | 28.18M |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| EBITDA | (4.88M) | (9.26M) | (7.33M) | (17.2M) | (21.2M) |
| EBITDA Margin | — | — | -122.2% | -483.9% | -266.8% |
| Operating Income | (4.87M) | (9.81M) | (7.9M) | (17.25M) | (20.27M) |
| Operating Margin | — | — | -131.7% | -485.4% | -255.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (21.48K) | (2.43M) | 639.37K | 1.65M | (957.4K) |
| Income Before Tax | (4.89M) | (12.24M) | (7.26M) | (15.6M) | (21.22M) |
| Pre-Tax Margin | — | — | -121.0% | -439.0% | -267.1% |
| Income Tax Expense | 0 | 0 | 723.85K | (720.29K) | 3.09K |
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Net Margin | — | — | -133.1% | -418.7% | -267.1% |
| EPS (Basic) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| EPS (Diluted) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| Weighted Avg Shares | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
| Weighted Avg Shares (Diluted) | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.